Novo Nordisk has regained investor confidence driven by strong demand for its Wegovy weight loss pill, which is helping stabilize its market share. While the company expects a 7% sales decline in 2024 due to U.S. pricing pressures, its international operations and oral GLP-1 products are offsetting these challenges. Novo Nordisk maintains robust operating margins above 41% and trades at a historically low price-to-earnings ratio of 14.1, making it an attractive buy opportunity as fundamentals improve and valuation remains appealing.
Novo Nordisk reported a decline in adjusted sales and operating profit for Q1 2026, yet its obesity care segment, particularly the Wegovy pill, showed strong growth and outperformed competitors like Eli Lilly. The company benefits from patent protect...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5%, driven by its obesity drug Mounjaro and new oral GLP-1 pill Foundayo, raising its full-year guidance. In contrast, Novo Nordisk saw a 4% adjusted sales decline, job cuts, and challenges inclu...
